Axsome Therapeutics, Inc. (NASDAQ:AXSM) CFO Nick Pizzie Sells 3,000 Shares

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CFO Nick Pizzie sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares in the company, valued at $5,529,450.09. This represents a 6.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Axsome Therapeutics Stock Down 0.4 %

AXSM stock opened at $131.15 on Monday. Axsome Therapeutics, Inc. has a fifty-two week low of $64.11 and a fifty-two week high of $134.18. The business’s 50 day moving average price is $97.84 and its two-hundred day moving average price is $93.37. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44. The company has a market capitalization of $6.36 billion, a price-to-earnings ratio of -20.08 and a beta of 1.05.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $121.00 target price on shares of Axsome Therapeutics in a report on Thursday, December 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $139.00 price target on shares of Axsome Therapeutics in a research report on Wednesday, January 29th. Bank of America raised their target price on Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. StockNews.com raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Wells Fargo & Company raised their price target on Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $147.13.

Institutional Trading of Axsome Therapeutics

Hedge funds have recently made changes to their positions in the stock. Assetmark Inc. bought a new stake in shares of Axsome Therapeutics in the 4th quarter worth approximately $52,000. R Squared Ltd bought a new stake in shares of Axsome Therapeutics in the 4th quarter worth approximately $64,000. Aquatic Capital Management LLC bought a new stake in shares of Axsome Therapeutics in the 4th quarter worth approximately $76,000. KBC Group NV boosted its position in shares of Axsome Therapeutics by 40.5% in the 4th quarter. KBC Group NV now owns 1,336 shares of the company’s stock worth $113,000 after purchasing an additional 385 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Axsome Therapeutics by 22.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after acquiring an additional 318 shares in the last quarter. 81.49% of the stock is owned by institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.